journal
https://read.qxmd.com/read/38472361/spotlight-on-the-real-world-treatment-of-cml-pts-in-germany-a-retrospective-survey-in-private-oncology-practices
#21
JOURNAL ARTICLE
Georg-Nikolaus Franke, Gunnar Loewe, Marcel Reiser, Hartmut Linde, Andreas Josting, Eyck von der Heyde, Uwe Platzbecker, Rudolf Weide, Hans Tesch, Arndt Nusch, Jolanta Dengler, Kathleen Jentsch-Ullrich
Clinical trials in chronic myeloid leukemia (CML) are usually carried out in specialized centers whereas primary care for patients (pts) with CML is mainly provided by local oncology practices. The aim of this study was to assess treatment practices in pts with CML in the setting of private oncology practices in Germany. We collected data of 819 pts with a confirmed diagnosis (dx) of CML in 2013 or later from 43 practices. At dx, 84.2% (n=690) and 9.4% (n=77) of pts were in chronic or accelerated phase, 0.7% (n=6) had a blast crisis...
March 12, 2024: Annals of Hematology
https://read.qxmd.com/read/38467825/secondary-hemophagocytic-lymphohistiocytosis-in-pediatric-patients-with-visceral-leishmaniasis-and-epstein-barr-virus-infection
#22
JOURNAL ARTICLE
Yuanfang Li, Sanjing Li, Nadan Lu, Weilin Wang, Dao Wang
Visceral leishmaniasis-associated hemophagocytic lymphohistiocytosis (VL-HLH) is indistinguishable from those of HLH of other etiologies due to the overlap symptoms, posing a serious threat to life. In this study, we aimed to provide insights for early diagnosis and improve outcomes in pediatric patients with VL-HLH. We retrospectively analyzed the clinical and laboratory data of 10 pediatric patients with VL-HLH and 58 pediatric patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH)...
March 12, 2024: Annals of Hematology
https://read.qxmd.com/read/38459156/rituximab-gemcitabine-and-oxaliplatin-in-relapsed-or-refractory-indolent-and-mantle-cell-lymphoma-results-of-a-multicenter-phase-i-ii-study-of-the-german-low-grade-lymphoma-study-group
#23
JOURNAL ARTICLE
Gabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, Luca Fischer, Michael Unterhalt, Christian Schmidt, Hans-Peter Böck, Ulrich Dührsen, Joachim Kaesberger, Stephan Kremers, Hans-Walter Lindemann, Luisa Mantovani, Wolfgang Hiddemann, Eva Hoster, Martin Dreyling
Rituximab, gemcitabine and oxaliplatin (R-GemOx) has demonstrated to be effective and safe in lymphoma patients. We aimed to determine the maximum tolerated dose (MTD) of oxaliplatin in combination with rituximab and gemcitabine and to explore the efficacy and safety of R-GemOx in relapsed or refractory (r/r) indolent and mantle cell lymphoma (MCL). In this single-arm, phase I/II trial, we enrolled 55 patients with r/r indolent lymphoma and MCL not suitable for autologous stem-cell transplantation. Patients received 4 cycles of R-GemOx...
March 9, 2024: Annals of Hematology
https://read.qxmd.com/read/38459155/very-long-term-efficacy-of-venetoclax-combined-with-hypomethylating-agents-in-two-aml-elderly-is-it-the-time-for-treatment-discontinuation-strategies
#24
LETTER
Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, Daniela Piccioni, Carla Mazzone, Paolo de Fabritiis
No abstract text is available yet for this article.
March 9, 2024: Annals of Hematology
https://read.qxmd.com/read/38459154/transformation-risk-and-associated-survival-outcome-of-marginal-zone-lymphoma-a-nationwide-study
#25
JOURNAL ARTICLE
Xu Sun, He Li, Yuqi Yang, Yijun Wu, Kai Kang, Qinyu Liu, Ren Luo, Li Wang, Ailin Zhao, Ting Niu
Histological transformation into an aggressive B-cell lymphoma indicates a poor survival outcome for patients with indolent marginal zone lymphoma (MZL), which has been less studied. Large-scale data with long-term follow-up to investigate MZL transformation is limited. Here, by reporting a US-Nationwide cohort of 30,619 MZL patients diagnosed between 2000 and 2019, we found that transformation occurred in 2.08% (N = 624) of MZL cases, with the transformation incidence of 3.1 per 1,000 person-years...
March 9, 2024: Annals of Hematology
https://read.qxmd.com/read/38459153/incidence-and-reasons-for-discontinuation-of-first-line-therapy-in-patients-with-multiple-myeloma-results-from-a-historical-cohort-brazil-2009-2020
#26
JOURNAL ARTICLE
Marina Xavier Teixeira, Adriano Max Moreira Reis, Paula Lana de Miranda Drummond, Jéssica Soares Malta, Lívia Pena Silveira, Cristiane Aparecida Menezes de Pádua
Multiple myeloma (MM) is an incurable hematological cancer requiring multiple lines of anti-myeloma regimens to promote disease remission and increase patient survival. The study assessed the incidence and reasons for discontinuation of first-line therapy in outpatients who started MM therapy in Belo Horizonte, Brazil from 2009 to 2020. A historical cohort study in which patients were followed from treatment initiation until discontinuation of first-line therapy. Discontinuation of first-line therapy was characterized as (i) discontinuation followed by a second-line therapy, and (ii) discontinuation that prevented patients from receiving a subsequent line of treatment...
March 9, 2024: Annals of Hematology
https://read.qxmd.com/read/38453704/validation-of-a-stenotrophomonas-maltophilia-bloodstream-infection-prediction-score-in-the-hematologic-malignancy-population
#27
JOURNAL ARTICLE
Emily L Gill, Christian M Gill, Colleen McEvoy
Stenotrophomonas maltophilia (SM) bloodstream infections (BSIs) contribute to significant mortality in hematologic malignancy (HM) and hematopoietic stem cell transplantation (HSCT) patients. A risk score to predict SM BSI could reduce time to appropriate antimicrobial therapy (TTAT) and improve patient outcomes. A single center cohort study of hospitalized adults with HM/HSCT was conducted. Patients had ≥ 1 blood culture with a Gram-negative (GN) organism. A StenoSCORE was calculated for each patient...
March 8, 2024: Annals of Hematology
https://read.qxmd.com/read/38453703/development-of-a-target-concentration-intervention-to-individualize-paroxysmal-nocturnal-hemoglobinuria-treatment-with-pegcetacoplan
#28
JOURNAL ARTICLE
Mendy Ter Avest, Saskia M C Langemeijer, Nicole M A Blijlevens, Nicole C A J van de Kar, Rob Ter Heine
Pegcetacoplan (Aspaveli®/Empaveli™) is a factor C3 inhibitor that is approved for the treatment of paroxysmal nocturnal hemoglobinuria. An individualized dosing strategy might be useful to improve patient-friendliness and cost-effectiveness of this very expensive drug. Therefore, the aim of this study was to develop an individualized treatment regimen for pegcetacoplan based on the pharmacokinetic-pharmacodynamic data of the manufacturer. We conducted a clinical trial simulation with the approved dosing regimen of 1080 mg twice-weekly and a target concentration intervention-based dosing regimen in patients with and without prior eculizumab use...
March 8, 2024: Annals of Hematology
https://read.qxmd.com/read/38453702/a-real-world-pharmacovigilance-study-investigating-the-toxicities-of-histone-deacetylase-inhibitors
#29
JOURNAL ARTICLE
Wenjie Li, Yiming Fu, Wei Wang
Histone deacetylase (HDAC) inhibitors are emerging as promising treatments for hematological malignancies, with potential applications extending to solid tumors in the future. Given their wide-ranging biological effects, there is a pressing need for a thorough understanding of the toxicities linked to HDAC inhibition. In this study, a pharmacovigilance analysis was conducted using the FDA Adverse Event Reporting System database. Suspected adverse events linked to HDAC inhibitors were detected through various statistical methodologies, including reporting odds ratio, proportional reporting ratio, information component, and Empirical Bayes Geometric Mean...
March 8, 2024: Annals of Hematology
https://read.qxmd.com/read/38451293/mutations-of-epigenetic-modifier-genes-predict-poor-outcome-in-adult-acute-lymphoblastic-leukemia
#30
JOURNAL ARTICLE
Jiawang Ou, Shiyu Deng, Chenhao Ding, Zihong Cai, Junjie Chen, Zicong Huang, Xiuli Xu, Jia Li, Zhengwei Wu, Bingqing Tang, Ting Zhang, Zhixiang Wang, Ya Zhou, Li Xuan, Qifa Liu, Hongsheng Zhou
Epigenetic modifier (EM) genes play important roles in the occurrence and progression of acute lymphoblastic leukemia (ALL). However, the prognostic significance of EM mutations in ALL has not yet been thoroughly investigated. This retrospective study included 205 adult patients with ALL engaged in a pediatric-type regimen. Based on targeted next-generation sequencing, they were divided into EM mutation group (EM-mut, n = 75) and EM wild-type group (EM-wt, n = 130). The EM-mut group showed a higher positive rate of minimal residual disease (MRD) on treatment day24 and before consolidation therapy (P = 0...
March 7, 2024: Annals of Hematology
https://read.qxmd.com/read/38448788/serum-cxcl13-level-is-related-to-treatment-response-and-predicts-disease-prognosis-in-waldenstr%C3%A3-m-macroglobulinemia
#31
JOURNAL ARTICLE
Jia Chen, Ming-Nan Jia, Hao Cai, Ze-Peng Li, Jian Li, Dao-Bin Zhou, Xin-Xin Cao
Waldenström macroglobulinemia (WM) is a type of B-cell lymphoma that produces IgM. Our study aimed to investigate the role of CXCL13, a chemokine essential for B lymphocytes, in the evaluation of treatment response and prognosis in WM. We collected serum samples and clinical data from 72 WM patients, with 69 patients receiving systemic therapy and 3 patients opting not to receive treatment. Serum CXCL13 levels at baseline and after six months of treatments were measured by enzyme-linked immunosorbent assay...
March 6, 2024: Annals of Hematology
https://read.qxmd.com/read/38448787/effect-of-prior-lenalidomide-or-daratumumab-exposure-on-hematopoietic-stem-cell-collection-and-reconstitution-in-multiple-myeloma
#32
REVIEW
Hongpeng Duan, Qiuhui Jiang, Long Liu, Manman Deng, Qian Lai, Yuelong Jiang, Zhifeng Li, Bing Xu, Zhijuan Lin
BACKGROUND: The roles of Lenalidomide (Len) and Daratumumab (Dara) in multiple myeloma treatment are well-established, yet their influences on hematopoietic stem cell harvesting and reconstitution remain disputed. METHODS: We conducted a systematic database review to identify cohort studies or RCTs evaluating the effect of the use of Len or Dara on hematopoietic stem cell collection and peripheral blood count recovery in multiple myeloma patients. Effects on hematopoietic collection or reconstitution were estimated by comparing standardized mean differences (SMD) and mean differences (MD), or median differences...
March 6, 2024: Annals of Hematology
https://read.qxmd.com/read/38443661/acute-myeloid-leukemia-with-rare-recurring-translocations-an-overview-of-the-entities-included-in-the-international-consensus-classification
#33
REVIEW
Synne D Rørvik, Synne Torkildsen, Øystein Bruserud, Tor Henrik Anderson Tvedt
Two different systems exist for subclassification of acute myeloid leukemia (AML); the World Health Organization (WHO) Classification and the International Consensus Classification (ICC) of myeloid malignancies. The two systems differ in their classification of AML defined by recurrent chromosomal abnormalities. One difference is that the ICC classification defines an AML subset that includes 12 different genetic abnormalities that occur in less than 4% of AML patients. These subtypes exhibit distinct clinical traits and are associated with treatment outcomes, but detailed description of these entities is not easily available and is not described in detail even in the ICC...
March 6, 2024: Annals of Hematology
https://read.qxmd.com/read/38443660/final-results-on-effectiveness-and-safety-of-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-from-the-non-interventional-fire-study
#34
JOURNAL ARTICLE
Caroline Dartigeas, Anne Quinquenel, Loïc Ysebaert, Marie-Sarah Dilhuydy, Bruno Anglaret, Borhane Slama, Katell Le Du, Stéphanie Tardy, Emmanuelle Tchernonog, Hubert Orfeuvre, Laurent Voillat, Stéphanie Guidez, Jean-Valère Malfuson, Sandrine Dupuis, Marine Deslandes, Pierre Feugier, Véronique Leblond
We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five years. Patients were included according to the French marketing authorization in 2016 (i.e. patients with relapsed or refractory CLL or to previously untreated CLL patients with deletion 17p and/or tumor protein p53 mutations unsuitable for chemoimmunotherapy) and could have initiated ibrutinib more than 30 days prior their enrolment in the study (i...
March 6, 2024: Annals of Hematology
https://read.qxmd.com/read/38441597/allogeneic-stem-cell-transplantation-is-still-a-highly-curative-therapy-in-adults-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukaemia
#35
JOURNAL ARTICLE
Lijuan Hu, Zongru Li, Sen Yang, Ting Zhao, Wenbing Duan, Yazhen Qin, Jinsong Jia, Jing Wang, Shengye Lu, Hao Jiang, Xiaohui Zhang, Lanping Xu, Yu Wang, Yueyun Lai, Hongxia Shi, Xiaojun Huang, Qian Jiang
The application of tyrosine kinase inhibitors (TKIs) and novel immunotherapies has improved outcomes in patients with Ph + acute lymphoblastic leukaemia (ALL), and the issue of whether there is still a need for stem cell transplantation has become controversial. We performed a retrospective study to explore whether stem cell transplantation still held a place in patients with Ph + ALL if only imatinib and 2nd generation TKIs are available and affordable. A total of 292 patients were included...
March 5, 2024: Annals of Hematology
https://read.qxmd.com/read/38438627/rop-et-a-prospective-phase-iii-trial-investigating-the-efficacy-and-safety-of-ropeginterferon-alfa-2b-in-essential-thrombocythemia-patients-with-limited-treatment-options
#36
JOURNAL ARTICLE
Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez-Larrán, Eloise Beggiato, Maria Bieniaszewska, Massimo Breccia, Veronika Buxhofer-Ausch, Olga Cerna, Ana-Manuela Crisan, Catalin Doru Danaila, Valerio De Stefano, Konstanze Döhner, Victoria Empson, Joanna Gora-Tybor, Martin Griesshammer, Sebastian Grosicki, Paola Guglielmelli, Valentin García-Gutierrez, Florian H Heidel, Arpád Illés, Ciprian Tomuleasa, Chloe James, Steffen Koschmieder, Maria-Theresa Krauth, Kurt Krejcy, Mihaela-Cornelia Lazaroiu, Jiri Mayer, Zsolt György Nagy, Franck-Emmanuel Nicolini, Francesca Palandri, Vassiliki Pappa, Andreas Johannes Reiter, Tomasz Sacha, Stefanie Schlager, Stefan Schmidt, Evangelos Terpos, Martin Unger, Albert Wölfler, Blanca Xicoy Cirici, Christoph Klade
Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they do not modify the natural history of the disease and hence, have no impact on disease progression. Ropeginterferon alfa-2b (trade name BESREMi®), a novel, monopegylated interferon alfa-2b with an extended administration interval, has demonstrated a robust and sustained efficacy in polycythemia vera (PV) patients...
March 4, 2024: Annals of Hematology
https://read.qxmd.com/read/38436672/intramedullary-leukocytoclastic-vasculitis-and-neutrophil-extracellular-trap-net-formation-in-poems-syndrome
#37
LETTER
Wiebke Aderhold, Benjamin Lenz, Marc P Hübner, Hans-Eckart Schaefer, Florian C Gaertner, Annkristin Heine, Ines Gütgemann
No abstract text is available yet for this article.
March 4, 2024: Annals of Hematology
https://read.qxmd.com/read/38433129/analysis-of-four-hereditary-protein-c-deficiencies-associated-with-vascular-thromboembolism
#38
JOURNAL ARTICLE
Xuanyu Chen, Chengxiang Yuan, Beilei Hu, Chunxing Lu, Yujia Wang, Zhao Han, Ming Zou
OBJECTIVE: To analyze the clinical features and gene mutations in four families with hereditary protein C (PC) deficiency and explore their association with vascular thromboembolism. METHODS: The clinical data of four patients with PC deficiency were retrospectively analyzed. Venous blood samples were collected from the four affected patients and their family members, and relevant coagulation indexes and thrombin production and inhibition tests were performed. PCR was used to amplify and directly sequence the PROC gene of the probands...
March 4, 2024: Annals of Hematology
https://read.qxmd.com/read/38436671/efficacy-and-safety-of-tixagevimab-cilgavimab-as-passive-immunisation-against-covid-19-infections-in-patients-with-hematological-malignancies
#39
JOURNAL ARTICLE
Patrick Reimann, Verena Petzer, Axel Mündlein, Bernd Hartmann, Luciano Severgnini, Alex Winkler, Theresia Lang, Minh Huynh, Klaus Gasser, Julia Rüger, Michele Atzl, Sylvia Mink, Peter Fraunberger, Stefan Schmidt, Normann Steiner, Andrea Griesmacher, Eberhard Gunsilius, David Nachbaur, Wolfgang Willenbacher, Dominik Wolf, Thomas Winder, Magdalena Anna Benda
Monoclonal antibodies, as tixagevimab/cilgavimab, have been introduced as prophylaxis against COVID-19 infections in high-risk populations. However, data on efficacy are limited. This study investigates efficacy and tolerability of tixagevimab/cilgavimab in hematological patients under real-life conditions. Tixagevimab/cilgavimab was administered to 155 hematological patients (March-August 2022) at two Austrian centres. S/RBD-antibody assessments were performed before (T0), four weeks (T1), and six months (T2) after application...
March 2, 2024: Annals of Hematology
https://read.qxmd.com/read/38430226/outcomes-of-haploidentical-peripheral-blood-stem-cell-transplantation-following-myeloablative-conditioning-using-two-types-of-rabbit-atg-a-propensity-score-matched-analysis
#40
JOURNAL ARTICLE
Zhuoyue Shi, Fei Gao, Dang Ding, Hengwei Wu, Jimin Shi, Yi Luo, Jian Yu, Yamin Tan, Xiaoyu Lai, Lizhen Liu, Huarui Fu, He Huang, Yanmin Zhao
During hematopoietic stem cell transplantation (HSCT), ATG depletes T cells in-vivo to improve engraftment and prevent graft-versus-host disease (GVHD). Here, we compared the clinical efficacy of two different types of ATGs: thymoglobulin and anti-human T-lymphocyte immunoglobulin (Grafalon). A total of 469 patients who received haploidentical transplantation were enrolled in this retrospective study. We applied a propensity score (PS)-matched analysis and 209 patients were assigned to each group. Clinical outcomes were compared between two groups and primary outcome was overall survival (OS)...
March 2, 2024: Annals of Hematology
journal
journal
30731
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.